LSTA

Business Context and Reporting Period

Company: NeoStem, Inc. (formerly Phase III Medical, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: NeoStem operates a commercial autologous adult stem cell bank, providing collection, processing, and long-term storage services. In January 2006, the Company acquired the assets of NS California, Inc., shifting its primary focus from providing capital to healthcare companies and running off an internet warranty business to the adult stem cell sector. The Company changed its name to NeoStem, Inc. in August 2006 to reflect this strategic pivot.

Key Financial Metrics (Year Ended Dec 31, 2006)

Note: The 2006 Net Loss includes significant non-cash expenses related to stock-based compensation ($560,465) and interest expense associated with the conversion of convertible notes ($871,813).

Material Changes vs. Prior Period

• Revenue Composition: While total revenue increased by 30%, the source shifted. Revenue from the legacy warranty business declined to $25,048 (from $35,262 in 2005). New revenue of $20,676 was generated from adult stem cell collection fees and physician start-up fees.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses surged 193% to $4.71 million. This increase was driven by the adoption of SFAS 123(R) requiring stock-based compensation recognition ($833,466 increase), higher payroll ($406,373 increase), and new business costs including marketing, legal, and laboratory expenses.
• Interest Expense: Interest expense increased 1,424% to $1.37 million, primarily due to the amortization of debt discounts and the fair value of warrants issued to debtholders in connection with the early conversion of WestPark convertible notes.
• Equity Position: The Company moved from a stockholders' deficit of $(1.82) million in 2005 to positive equity of $292,105 in 2006, largely due to significant capital raises and the conversion of Series A Preferred Stock into Common Stock.

Guidance, Outlook, Risks, and Unusual Items

Capital Raising and Liquidity

The Company raised approximately $3.57 million in 2006 through private placements (June and Summer 2006). In early 2007 (subsequent to year-end), the Company raised an additional $2.5 million (net proceeds ~$2.3 million) via a private placement of units consisting of common stock and warrants. Management states that substantial additional financing will be required to fund operations and commercialization.

Outlook and Strategy

NeoStem plans to expand its physician network and collection centers (recently expanded to Las Vegas and Eastern Pennsylvania in March 2007). The Company intends to generate recurring revenue from storage fees and utilization fees once stem cell therapies become standard of care. The legacy warranty business is in "run-off" and is expected to end in 2007.

Risks and Contingencies

• Liquidity Risk: The Company has a history of operating losses and a working capital deficit. Continued losses are expected until commercialization is achieved.
• Regulatory Risk: Operations are subject to FDA regulations (cGTP) and state biologics licensing. Failure to comply could result in injunctions or fines.
• Market Acceptance: Success depends on the clinical validation of adult stem cell therapies and market acceptance of the banking service.
• Competition: The Company faces competition from established cord blood banks and hospitals with greater resources.

Unusual Items

The 2006 financials include a $250,000 settlement expense with a former officer (Robert Aholt) and significant non-cash interest expenses related to the restructuring and conversion of convertible promissory notes.

Investor Verification Checklist

• Cash Burn Rate: Verify the current cash balance against the monthly operating burn rate to assess runway, given the history of losses.
• Revenue Recognition: Confirm the specific timing and criteria for recognizing stem cell collection and storage fees, as this is a new revenue stream.
• Stock-Based Compensation: Review the valuation assumptions (Black-Scholes inputs) used for stock options and warrants, which significantly impact reported net loss.
• Convertible Debt Status: Verify the status of any remaining convertible notes and the dilution impact of outstanding warrants (over 6 million shares reserved as of Dec 31, 2006).
• Regulatory Compliance: Confirm the status of the California biologics license and any pending FDA registration requirements.
• Related Party Transactions: Review the terms of the office lease with an affiliate of Duncan Capital Group and the advisory agreements with financial consultants.